Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib and Lenalidomide with R-ICE for R/R DLBCL
NCT06033820Phase 2Recruiting
- Sponsor
- Renji Hospital
- Start
- Oct 2023
- Primary completion
- Jun 2025
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zanubrutinib and lenalidomide in diffuse large B-cell lymphoma (DLBCL), sponsored by Renji Hospital. Primary endpoint: Objective Response Rate at 9 weeks. Started Oct 2023; status: recruiting.
02
Drugs
zanubrutiniblenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06033820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06033820.